26 Jul Viralgen
Andy Holt, Chief Commercial Officer
Oct. 7 | 1:45pm | FLW Ballroom G
San Sebastian, Spain
(Private)
Viralgen is a leading CDMO specializing exclusively in AAV-based gene therapies, offering end-to-end support from early development to commercial production. Using our proprietary Pro10™ suspension platform, we achieve high-yield, scalable manufacturing across all AAV serotypes. With cGMP-certified facilities in San Sebastián, Spain, we provide integrated services including plasmid production, process optimization, fill-finish, and in-house QC testing. Our approach accelerates development timelines while controlling cost-of-goods. With over 1,500 AAV batches produced and a strong regulatory track record, Viralgen delivers reliable, efficient solutions that help bring gene therapies to patients with greater speed and consistency.
